A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Administration of SB743921 on a Once Every 3 Week Schedule in Patients With Solid Tumors.
Latest Information Update: 22 Aug 2023
At a glance
- Drugs SB 743921 (Primary)
- Indications B-cell lymphoma; Solid tumours; T-cell lymphoma
- Focus Adverse reactions
- Sponsors GSK
- 15 Oct 2008 Actual start date changed from Feb 2004 to Apr 2004 as reported by Clinicaltrials.gov.
- 15 Oct 2005 New trial record.